The endocannabinoid transport inhibitor AM404 modulates nociception in cholestasis
- PMID: 19616063
- DOI: 10.1016/j.neulet.2009.07.026
The endocannabinoid transport inhibitor AM404 modulates nociception in cholestasis
Abstract
Cholestasis is associated with increased activity of the endogenous opioid system that results in analgesia. Endocannabinoid system can reduce pain sensitivity. Considering the interaction that has been shown between the endogenous opioid and endocannabinoid systems in nociception processing, we studied the effect of AM404, an endocannabinoid transport inhibitor, on modulation of nociception in cholestasis, a model of elevated endogenous opioid tone. Cholestasis was induced by ligation of the main bile duct using two ligatures and transection of the duct at the midpoint between them. A significant increase (P<0.01) in TF was observed in cholestatic rats compared to unoperated and sham rats. AM404 (10 mg/kg, i.p.) significantly increased TFL at 5, 30 min but not 60 min after injection in cholestatic animals compared to the vehicle treated cholestatic group (P<0.05, P<0.001, respectively). AM404 injection to unoperated and sham rats did not alter baseline TFL. The effect of AM404 in cholestatic rats was blocked by co-administration of a CB(1) receptor antagonist, AM251 (1 mg/kg, i.p.) but not by the CB2 receptor antagonist, SR144528 (1 mg/kg, i.p.). Naloxone injection blocked the antinociception induced by cholestasis in bile duct ligated group. Antinociception produced by injection of AM404 in cholestatics was also attenuated by co-administration of naloxone. These data show that AM404 potentiates antinociception induced by cholestasis and indicate that there are possible interactions between opioid and cannabinoid systems in this experimental model of elevated endogenous opioid tone. The inhibitory effects of AM404 in this model are mediated by cannabinoid CB(1) and not CB(2) receptors.
Similar articles
-
A potent and selective inhibitor of endocannabinoid uptake, UCM707, potentiates antinociception induced by cholestasis.Fundam Clin Pharmacol. 2008 Oct;22(5):517-22. doi: 10.1111/j.1472-8206.2008.00626.x. Fundam Clin Pharmacol. 2008. PMID: 18844724
-
Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis.Eur J Pharmacol. 2008 Sep 4;591(1-3):132-5. doi: 10.1016/j.ejphar.2008.06.061. Epub 2008 Jun 19. Eur J Pharmacol. 2008. PMID: 18593578
-
Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models.Clin Exp Pharmacol Physiol. 2007 Nov;34(11):1186-90. doi: 10.1111/j.1440-1681.2007.04692.x. Clin Exp Pharmacol Physiol. 2007. PMID: 17880375
-
Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology.J Pharmacol Exp Ther. 2001 Jul;298(1):7-14. J Pharmacol Exp Ther. 2001. PMID: 11408519 Review.
-
Cannabinoid Receptor Type 1 and Its Role as an Analgesic: An Opioid Alternative?J Dual Diagn. 2020 Jan-Mar;16(1):106-119. doi: 10.1080/15504263.2019.1668100. Epub 2019 Oct 9. J Dual Diagn. 2020. PMID: 31596190 Free PMC article. Review.
Cited by
-
Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors.J Biol Chem. 2012 Jan 27;287(5):3415-24. doi: 10.1074/jbc.M111.304907. Epub 2011 Dec 14. J Biol Chem. 2012. PMID: 22170058 Free PMC article.
-
On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence.Neurotox Res. 2021 Dec;39(6):2072-2097. doi: 10.1007/s12640-021-00424-z. Epub 2021 Nov 6. Neurotox Res. 2021. PMID: 34741755 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous